Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro Adjuvant Nivo+Ipi Fails in Kidney Cancer, in Contrast to Pembro

Six months of adjuvant nivolumab plus ipilimumab after nephrectomy for renal cell carcinoma offers no disease-free survival benefit, reveals trial that highlights treatment duration and tolerability.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news